Recent Advances in Gynecological Malignancies: Focus on ASCO 2023.
作者信息
Bodriagova Olga, Previs Rebecca Ann, Gaba Lydia, Shankar Abhishek, Vidal Laura, Saini Kamal S
机构信息
Fortrea Inc., 8, Moore Drive, Durham, NC, 27709, USA.
Division of Gynecologic Oncology, Department of Obstetrics and Gynecology, Duke University Medical Center, Durham, USA.
出版信息
Oncol Ther. 2023 Dec;11(4):397-409. doi: 10.1007/s40487-023-00244-5. Epub 2023 Sep 15.
Abstract
摘要
相似文献
1
Recent Advances in Gynecological Malignancies: Focus on ASCO 2023.妇科恶性肿瘤的最新进展：聚焦2023年美国临床肿瘤学会（ASCO）年会
Oncol Ther. 2023 Dec;11(4):397-409. doi: 10.1007/s40487-023-00244-5. Epub 2023 Sep 15.
2
New Targeted Therapies and Combinations of Treatments for Cervical, Endometrial, and Ovarian Cancers: A Year in Review.新的靶向治疗和治疗宫颈癌、子宫内膜癌和卵巢癌的联合治疗方案：年度回顾。
Curr Oncol. 2022 Apr 17;29(4):2835-2847. doi: 10.3390/curroncol29040231.
3
[Clinical analysis of 23 cases with simultaneous double primary gynecological malignant tumors].23例同时性双原发性妇科恶性肿瘤的临床分析
Zhonghua Fu Chan Ke Za Zhi. 2022 May 25;57(5):352-360. doi: 10.3760/cma.j.cn112141-20220214-00086.
4
Advances in immunotherapy for gynecological malignancies.妇科恶性肿瘤的免疫治疗进展。
Crit Rev Oncol Hematol. 2023 Aug;188:104063. doi: 10.1016/j.critrevonc.2023.104063. Epub 2023 Jun 28.
5
Immunotherapy and Its Development for Gynecological (Ovarian, Endometrial and Cervical) Tumors: From Immune Checkpoint Inhibitors to Chimeric Antigen Receptor (CAR)-T Cell Therapy.免疫疗法及其在妇科（卵巢、子宫内膜和宫颈）肿瘤中的发展：从免疫检查点抑制剂到嵌合抗原受体（CAR）-T细胞疗法。
Cancers (Basel). 2021 Feb 17;13(4):840. doi: 10.3390/cancers13040840.
6
Annual report of the committee on gynecologic oncology, the Japan Society of Obstetrics and Gynecology: Annual patient report for 2019 and annual treatment report for 2014.日本妇产科协会妇科肿瘤学委员会年度报告：2019 年年度患者报告和 2014 年年度治疗报告。
J Obstet Gynaecol Res. 2022 Jul;48(7):1570-1579. doi: 10.1111/jog.15284. Epub 2022 May 27.
7
Gynecological malignancies at tertiary care hospital, Pakistan: A five-year review.巴基斯坦三级护理医院的妇科恶性肿瘤：五年回顾
Pak J Med Sci. 2021 May-Jun;37(3):621-627. doi: 10.12669/pjms.37.3.3596.
8
Annual report of the Committee on Gynecologic Oncology, the Japan Society of Obstetrics and Gynecology: Annual Patient Report for 2020 and Annual Treatment Report for 2015.日本妇产科学会妇科肿瘤学委员会年度报告：2020年年度患者报告及2015年年度治疗报告
J Obstet Gynaecol Res. 2023 Nov;49(11):2584-2592. doi: 10.1111/jog.15767. Epub 2023 Aug 21.
9
Gynecological malignancies in Aminu Kano Teaching Hospital Kano: a 3 year review.卡诺阿明努·卡诺教学医院的妇科恶性肿瘤：三年回顾
Niger J Clin Pract. 2013 Jan-Mar;16(1):63-6. doi: 10.4103/1119-3077.106768.
10
Annual report of the Committee on Gynecologic Oncology, the Japan Society of Obstetrics and Gynecology: Annual Patient Report for 2018 and Annual Treatment Report for 2013.日本妇产科协会妇科肿瘤学委员会年度报告：2018 年年度患者报告和 2013 年年度治疗报告。
J Obstet Gynaecol Res. 2022 Mar;48(3):541-552. doi: 10.1111/jog.15134. Epub 2022 Jan 13.
引用本文的文献
1
Lifestyle factors affecting the prognosis of gynecological cancer: systematic review and meta-analysis.影响妇科癌症预后的生活方式因素：系统评价与荟萃分析
Cancer Causes Control. 2025 Aug 26. doi: 10.1007/s10552-025-02059-3.
2
Multi-omics based and AI-driven drug repositioning for epigenetic therapy in female malignancies.基于多组学和人工智能驱动的女性恶性肿瘤表观遗传治疗药物重新定位
J Transl Med. 2025 Jul 25;23(1):837. doi: 10.1186/s12967-025-06856-x.
本文引用的文献
1
Camrelizumab plus apatinib in patients with advanced or recurrent endometrial cancer after failure of at least one prior systemic therapy (CAP 04): a single-arm phase II trial.卡瑞利珠单抗联合阿帕替尼治疗至少一线治疗失败的晚期或复发性子宫内膜癌患者（CAP04）：一项单臂、II 期临床试验。
BMC Med. 2024 Aug 26;22(1):344. doi: 10.1186/s12916-024-03564-z.
2
Efficacy and Safety of Sacituzumab Govitecan in Patients With Advanced Solid Tumors (TROPiCS-03): Analysis in Patients With Advanced Endometrial Cancer.在晚期实体瘤患者中（TROPiCS-03）：晚期子宫内膜癌患者分析Sacituzumab Govitecan 的疗效和安全性。
J Clin Oncol. 2024 Oct 10;42(29):3421-3429. doi: 10.1200/JCO.23.02767. Epub 2024 Jul 31.
3
First-Line Pembrolizumab + Chemotherapy Versus Placebo + Chemotherapy for Persistent, Recurrent, or Metastatic Cervical Cancer: Final Overall Survival Results of KEYNOTE-826.一线帕博利珠单抗+化疗对比安慰剂+化疗用于持续性、复发性或转移性宫颈癌：KEYNOTE-826 的最终总生存结果。
J Clin Oncol. 2023 Dec 20;41(36):5505-5511. doi: 10.1200/JCO.23.00914. Epub 2023 Nov 1.
4
Efficacy and Safety of Trastuzumab Deruxtecan in Patients With HER2-Expressing Solid Tumors: Primary Results From the DESTINY-PanTumor02 Phase II Trial.曲妥珠单抗-德鲁替康在 HER2 表达的实体瘤患者中的疗效和安全性：来自 DESTINY-PanTumor02 Ⅱ期试验的初步结果。
J Clin Oncol. 2024 Jan 1;42(1):47-58. doi: 10.1200/JCO.23.02005. Epub 2023 Oct 23.
5
Cytoreductive surgery with or without hyperthermic intraperitoneal chemotherapy in patients with advanced ovarian cancer (OVHIPEC-1): final survival analysis of a randomised, controlled, phase 3 trial.细胞减灭术联合或不联合腹腔热灌注化疗治疗晚期卵巢癌患者（OVHIPEC-1）：一项随机对照 3 期临床试验的最终生存分析。
Lancet Oncol. 2023 Oct;24(10):1109-1118. doi: 10.1016/S1470-2045(23)00396-0. Epub 2023 Sep 11.
6
Neoadjuvant camrelizumab plus chemotherapy for locally advanced cervical cancer (NACI Study): a study protocol of a prospective, single-arm, phase II trial.卡瑞利珠单抗联合化疗新辅助治疗局部晚期宫颈癌（NACI 研究）：一项前瞻性、单臂、Ⅱ期临床试验研究方案。
BMJ Open. 2023 May 30;13(5):e067767. doi: 10.1136/bmjopen-2022-067767.
7
HIPEC for gynaecological malignancies: A last update (Review).妇科恶性肿瘤的腹腔热灌注化疗：最新进展（综述）
Med Int (Lond). 2023 May 4;3(3):25. doi: 10.3892/mi.2023.85. eCollection 2023 May-Jun.
8
PARP inhibitors and overall survival in ovarian cancer, reevaluation advised in all settings.聚腺苷二磷酸核糖聚合酶抑制剂与卵巢癌的总生存期，建议在所有情况下重新评估。
J Cancer Res Clin Oncol. 2023 Sep;149(11):9509-9512. doi: 10.1007/s00432-023-04748-5. Epub 2023 May 10.
9
Dostarlimab for Primary Advanced or Recurrent Endometrial Cancer.度伐利尤单抗治疗原发性晚期或复发性子宫内膜癌。
N Engl J Med. 2023 Jun 8;388(23):2145-2158. doi: 10.1056/NEJMoa2216334. Epub 2023 Mar 27.
10
Tisotumab vedotin in recurrent or metastatic cervical cancer.替索妥单抗（Tisotumab vedotin）治疗复发性或转移性宫颈癌
Curr Probl Cancer. 2023 Jun;47(3):100952. doi: 10.1016/j.currproblcancer.2023.100952. Epub 2023 Feb 10.
Zotero 插件